Project Title

A study comparing Abelacimab to Apixaban in the treatment of cancer-associated VTE

Official Title

A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of Abelacimab relative to Apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer-associated VTE.

Project Summary

Cancer associated thrombosis (CAT) is a severe medical condition which is characterized by high incidence of Venous thromboembolism (VTE) recurrence and high risk for bleeding. The two most common treatments today are low molecular weight heparin (LMWH) and direct anticoagulants (DOACs), in which each has limitations. DOACs are administered orally and are seen as a more convenient alternative though associated with bleeding risk; further, some cancer patients have difficulty swallowing or develop vomiting which leads to unpredictable pharmacodynamic effects with oral therapy. The ANT-007 study will compare treatment with abelacimab monthly administration to apixaban twice daily administration over a 6-month treatment. The study outcomes include VTE recurrence, bleeding event and treatment discontinuation at 6 months.

Blood Disorder

• Venous thromboembolism
• Deep venous thromboembolism
• Pulmonary embolism

Patient Recruitment Details

Patient recruitment status: open

Number of patients (Globally)

1655